Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 1, 2006, Pages 68-73

  Norsa, Achille ^a   Martino, Vincenzo ^b  

^a MAGGIORE HOSPITAL   (Italy)

^b Società Italiana di Bioterapia Oncologica Razionale   (Italy)

Author keywords

Bromocriptine; Cyclophosphamide; ECOG PS; Melatonin; NSCLC; Somatostatin; Vitamins

Indexed keywords

BETA CAROTENE; BROMOCRIPTINE; CYCLOPHOSPHAMIDE; DIHYDROTACHYSTEROL; MELATONIN; RETINOIC ACID; RETINOID; RETINOL PALMITATE; SOMATOSTATIN; VITAMIN D;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DROWSINESS; DYSPNEA; FATIGUE; FEMALE; HUMAN; INSOMNIA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

ADULT; AGED; BROMOCRIPTINE; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MALE; MELATONIN; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; RETINOIDS; SOMATOSTATIN; SURVIVAL ANALYSIS; TIME FACTORS; VITAMIN D;

EID: 33644912577     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.68     Document Type: Article

References (31)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533.
2. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710.
3. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small-cell lung cancer: A meta-analysis. Lancet 1993;342:19.
4. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-Small-Cell Lung Cancer Collaborative Group. BMJ 1995;311:899.
5. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy versus supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994;106:861.
6. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell-lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991;9:1618.
7. Takigawa N, Segawa Y, Okahara M, et al. Prognostic factors for patients with advanced non-small cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 1996;15:67.
8. Bunn PA, Jr. Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why? J Clin Oncol 2002;20:23S.
9. Soria JC, Brisgand D, Le Chevalier T. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 2001;12:1667.
10. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002;20:3578.
11. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and nonplatinum-based chemotherapy in advanced non-small-cell lung cancer: A randomized multicenter trial. Lancet 2001;357:1478.
12. Dy GK, Adjei AA. Novel targets for lung cancer therapy: Part I. J Clin Oncol 2002;20:2881.
13. Di Bella L, Rossi MT, Scalera G. Perspectives in pineal functions. Prog Brain Res 1979;52:475.
14. Todisco M, Casaccia P, Rossi N. Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin, and ACTH in the treatment of low-grade non-Hodgkin's lymphomas at advanced stage: Results of a phase II trial. Cancer Biother Radiopharm 2001;16:171.
15. Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet 1998;352:1455.
16. Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition 2000;16:1084.
17. Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem 2002;2:167.
18. O'Byrne KJ, Schally AV, Thomas A, et al. Somatostatin, its receptors and analogs, in lung cancer. Chemotherapy 2001;47(Suppl 2):78.
19. Dasgupta P. Somatostatin analogs: Multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 2004;102:61.
20. Toma S, Raffo P, Isnardi L, et al. Retinoids in lung cancer chemoprevention and treatment. Ann Oncol 1999;10(Suppl 5):S95.
21. Lissoni P. Is there a role for melatonin in supportive care? Supp Care Cancer 2002;10:110.
22. Vijayalaxmi, Thomas CR, Jr, Reiter RJ, et al. Melatonin: From basic research to cancer treatment clinics. J Clin Oncol 2002;20:2575.
23. Conti A, Maestroni GJ. The clinical neuroimmunotherapeutic role of melatonin in oncology. J Pineal Res 1995;19:103.
24. Lissoni P, Chilelli M, Villa S, et al. Five years survival in metastatic non-small-cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial. J Pineal Res 2003;35:12.
25. Banerjee P, Chatterjee M. Antiproliferative role of vitamin D and its analogs-a brief overview. Mol Cell Biochem 2003;253:247.
26. Trump DL, Hershberger PA, Bernardi RJ, et al. Antitumoural activity of calcitriol: Preclinical and clinical studies. J Steroid Biochem Mol Biol 2004;89-90:519.
27. Kelly K. Challenges in defining and identifying patients with non-small-cell lung cancer and poor performance status. Semin Oncol 2004;31:3.
28. Blackball FH, Bhosle J, Thatcher N. Chemotherapy for advanced non-small-cell lung cancer patients with performance status 2. Curr Opin Oncol 2005;17:135.
29. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996.
30. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92.
31. Isla D, Rosell R, Sanchez JJ, et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2001;19:1071.